<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849560</url>
  </required_header>
  <id_info>
    <org_study_id>GriQv-III-16</org_study_id>
    <nct_id>NCT03849560</nct_id>
  </id_info>
  <brief_title>Safety, Reactogenicity, Immunogenicity, and Efficacy of Quadrivalent Inactivated Subunit Influenza Vaccine Grippol® Quadri and Trivalent Inactivated Polymer-Subunit Vaccine Grippol® Plus in Volunteers</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Comparative Study of Safety, Reactogenicity, Immunogenicity, and Efficacy of Quadrivalent Inactivated Subunit Influenza Vaccine Grippol® Quadri (NPO Petrovax Pharm, LLC, Russia) and Trivalent Inactivated Polymer-Subunit Vaccine Grippol® Plus (NPO Petrovax Pharm, LLC, Russia) in Parallel Groups, in Volunteers of 18 to 60 Years Old.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NPO Petrovax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NPO Petrovax</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first Russian quadrivalent influenza vaccine was developed to improve the effectiveness&#xD;
      of vaccination and the cost-effectiveness of preventive immunization.Current study was&#xD;
      conducted to assess the safety, reactogenicity, immunogenicity, and efficacy of quadrivalent&#xD;
      inactivated subunit influenza vaccine Grippol® Quadri (NPO Petrovax Pharm, LLC, Russia)&#xD;
      versus trivalent inactivated polymer-subunit vaccine Grippol® Plus (NPO Petrovax Pharm, LLC,&#xD;
      Russia) in subjects from 18 to 60 years old.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The share of subjects achieving seroconversion increased more than 4-fold versus baseline for antigens: influenza virus type А - H1N1, influenza virus type А - H3N2, influenza virus type В - Yamagata and Victoria lineage</measure>
    <time_frame>Day 21 after immunization (Visit 7)</time_frame>
    <description>The share of subjects achieving seroconversion (the number of volunteers with antibody titer [of at least 1:40] increased more than 4-fold versus baseline [assessed by HAIR]) for antigens: influenza virus type А - H1N1, influenza virus type А - H3N2, influenza virus type В - Yamagata and Victoria lineage, based on assessment at Visit 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coefficient of increase of mean geometric antibody titer</measure>
    <time_frame>Day 21 after immunization (Visit 7)</time_frame>
    <description>For antigens H1N1, H3N2, Yamagata and Victoria lineages Based on assessment at Visit 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean of serum antibodies</measure>
    <time_frame>Day 21 after immunization (Visit 7)</time_frame>
    <description>To antigens: influenza virus type А - H1N1, influenza virus type А - H3N2, influenza virus type В - Yamagata and Victoria lineage/ Based on assessment at Visit 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection</measure>
    <time_frame>Day 21 after immunization (Visit 7)</time_frame>
    <description>: share of subjects achieving protective antibody titer (1:40 and more) to antigens H1N1, H3N2, Yamagata and Victoria lineage.&#xD;
Based on assessment at Visit 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of influenza and ARI</measure>
    <time_frame>Day 180±5 after immunization (Visit 11).</time_frame>
    <description>Based on assessment at Visit 11.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity and duration of reported cases of influenza and ARI</measure>
    <time_frame>Day 180±5 after immunization (Visit 11).</time_frame>
    <description>Severity and duration of reported cases of influenza and ARI, complications.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">609</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Grippol® Quadri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)&#xD;
Active ingredients:&#xD;
type A (H1N1) influenza virus antigen 5 µg;&#xD;
type A (H3N2) influenza virus antigen 5 µg;&#xD;
type B (Yamagata lineage) influenza virus antigen 5 µg;&#xD;
type B (Victoria lineage) influenza virus antigen 5 µg;&#xD;
immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grippol® Plus, trivalent (Yamagata lineage)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.&#xD;
Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)&#xD;
Active ingredients:&#xD;
type A (H1N1) influenza virus antigen 5 µg;&#xD;
type A (H3N2) influenza virus antigen 5 µg;&#xD;
type B (Yamagata lineage) influenza virus antigen 5 µg;&#xD;
immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grippol® Plus, trivalent (Victoria lineage)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.&#xD;
Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)&#xD;
Active ingredients:&#xD;
type A (H1N1) influenza virus antigen 5 µg;&#xD;
type A (H3N2) influenza virus antigen 5 µg;&#xD;
type B (Victoria lineage) influenza virus antigen 5 µg;&#xD;
immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Grippol® Quadri</intervention_name>
    <description>Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).</description>
    <arm_group_label>Grippol® Quadri</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Grippol® Plus, trivalent (Yamagata lineage)</intervention_name>
    <description>Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).</description>
    <arm_group_label>Grippol® Plus, trivalent (Yamagata lineage)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Grippol® Plus, trivalent (Victoria lineage)</intervention_name>
    <description>Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).</description>
    <arm_group_label>Grippol® Plus, trivalent (Victoria lineage)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated volunteer's informed consent for participation in the study.&#xD;
&#xD;
          2. Men and women from 18 to 60 years old.&#xD;
&#xD;
          3. Healthy volunteers without signs of acute or chronic disorders, without history of&#xD;
             chronic respiratory, cardiovascular, nervous system disorders, hepatic or renal&#xD;
             disorders.&#xD;
&#xD;
          4. Previously not immunized, or previous influenza immunization occurring ≥ 12 months&#xD;
             before this study.&#xD;
&#xD;
          5. Subjects without history of influenza within ≥ 12 months before this study.&#xD;
&#xD;
          6. Consent of volunteers (men and women) to use adequate methods of contraception&#xD;
             (cervical caps with spermicide, diaphragms with spermicide, condoms with spermicide,&#xD;
             intrauterine devices, oral contraceptives) or full abstinence for the whole period of&#xD;
             the study.&#xD;
&#xD;
        Specific:&#xD;
&#xD;
          1. Contraindications listed in the protocol and prescribing information for inactivated&#xD;
             influenza vaccines:&#xD;
&#xD;
               -  acute infections and non-communicable disorders, including the period of&#xD;
                  reconvalescence of at least one month from the time of clinical and laboratory&#xD;
                  evidence of recovery;&#xD;
&#xD;
               -  hepatitis or meningococcal infection occurred less than 6 months after recovery;&#xD;
&#xD;
               -  exacerbations of chronic disorder or decompensated disorders that may impact the&#xD;
                  study (organic central nervous system disorders, decompensated cardiovascular&#xD;
                  disorder, acute renal or hepatic failure);&#xD;
&#xD;
               -  malignant neoplasms (including hematological disorders);&#xD;
&#xD;
               -  primary immunodeficiency (laboratory-confirmed);&#xD;
&#xD;
               -  HIV infection or HIV-associated disorders;&#xD;
&#xD;
               -  systemic disorders of connective tissue;&#xD;
&#xD;
               -  haemophilia (and other blood coagulation disorders);&#xD;
&#xD;
               -  severe neurological disorders;&#xD;
&#xD;
               -  Guillain-Barré syndrome (post infection demyelinating polyradiculoneuropathy of&#xD;
                  autoimmune nature with peripheral limb muscle palsy related to inflammation and&#xD;
                  destruction of myelin sheath of peripheral nerves; may acquire an ascending&#xD;
                  nature, involving muscles of face, pharynx, larynx);&#xD;
&#xD;
               -  history of severe vaccine-associated reactions (body temperature exceeding 38.5&#xD;
                  °С) or local reactions (hyperemia and/or oedema at the site of injection of over&#xD;
                  5 cm in diameter);&#xD;
&#xD;
               -  history of severe allergic disorders (angioedema, polymorphic exudative erythema,&#xD;
                  serum disease, etc.);&#xD;
&#xD;
               -  hypersensitivity to chicken protein or vaccine components;&#xD;
&#xD;
               -  blood and components transfusion within the last 6 months.&#xD;
&#xD;
          2. Indications for immunomodulating therapy.&#xD;
&#xD;
          3. Body temperature over 37.0 °С at screening or before injection.&#xD;
&#xD;
          4. Potential evidence of a chronic infection (periodic episodes of fever within the last&#xD;
             6 months), or antiviral (and/or antibacterial) treatment indicated.&#xD;
&#xD;
          5. History of disorders or conditions, which, according to investigator's judgment may&#xD;
             impact the thermal regulation (chronic infections, neuroendocrine disorders&#xD;
             [thyrotoxicosis, pheochromocytoma, etc.], climacteric syndrome, malignant&#xD;
             hyperthermia, CNS disorders, malignant neoplasm, connective tissue disorders, systemic&#xD;
             vasculitis, and information on excessive physical stress or work-rest regimen&#xD;
             deviations [within the last 2 months: night shifts, significant change of time zones,&#xD;
             overheating]).&#xD;
&#xD;
          6. Use of antipyretics (including non-steroidal anti-inflammatory drugs and anilides)&#xD;
             within 24 hours before randomization.&#xD;
&#xD;
          7. Surgical interventions within less than 90 days before the screening visit.&#xD;
&#xD;
          8. Systolic blood pressure of over 130 mm Hg or less than 100 mm Hg and/or diastolic&#xD;
             blood pressure of over 90 mm Hg or less than 60 mm Hg.&#xD;
&#xD;
          9. Any other disorder, which, in the opinion of the investigator, may prevent inclusion&#xD;
             of the volunteer due to safety reasons or may impact the study results.&#xD;
&#xD;
             General:&#xD;
&#xD;
         10. Pregnant and nursing women.&#xD;
&#xD;
         11. Lack of ability to visit daytime inpatient facility according to the study schedule,&#xD;
             unavailability for adequate follow-up of the volunteer.&#xD;
&#xD;
         12. Body mass index of less than 18.5 or over 30.0 kg/m2 based on the weight-height&#xD;
             Quetelet's index.&#xD;
&#xD;
         13. Participation in another clinical study of medicinal drugs within 3 months before the&#xD;
             start of this study.&#xD;
&#xD;
         14. Mental, physical, or other reasons which prevent adequate assessment of own behavior&#xD;
             and prevent from meeting the study protocol conditions.&#xD;
&#xD;
         15. History of narcotic and/or drug abuse, and/or inhalant addiction, current signs of&#xD;
             alcoholic intoxication.&#xD;
&#xD;
         16. Intake of at least 5 alcohol units per week or history of alcohol, drug, or medicinal&#xD;
             product abuse. One alcohol unit corresponds to 360 ml of beer, 120 ml of wine, or 30&#xD;
             ml of a strong alcoholic beverage.&#xD;
&#xD;
         17. Suspected lack of compliance with treatment or inability to undergo treatment and&#xD;
             observe the limitations according to the study protocol.&#xD;
&#xD;
         18. Volunteers acknowledged by the court to be disabled or under guardianship.&#xD;
&#xD;
         19. Any other conditions that make the volunteer ineligible for the study according to a&#xD;
             justified opinion of the study doctor or Sponsor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Informed consent recall.&#xD;
&#xD;
          -  Occurrence of a severe AE or serious adverse events.&#xD;
&#xD;
          -  The volunteer is found to meet any of the non-inclusion criteria related to the safety&#xD;
             of the volunteer participation in the study.&#xD;
&#xD;
          -  If a female-volunteer becomes pregnant.&#xD;
&#xD;
          -  The volunteer takes medicines not allowed in this study.&#xD;
&#xD;
          -  The volunteer is lost to follow-up.&#xD;
&#xD;
          -  In a situation, which, to the investigator's judgment, may adversely impact the&#xD;
             volunteer if he/she continues participating in the study.&#xD;
&#xD;
          -  For administrative reasons (study termination by the Sponsor or regulatory&#xD;
             authorities) or in case of major protocol violations which may significantly impact&#xD;
             the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Smorodintsev Research Institute of Influenza</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningrad Oblast</state>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NPO Petrovax</investigator_affiliation>
    <investigator_full_name>Elvira Mukhametshina</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 1, 2019</submitted>
    <returned>June 12, 2019</returned>
    <submitted>November 12, 2020</submitted>
    <returned>December 9, 2020</returned>
    <submitted>September 14, 2021</submitted>
    <returned>October 11, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

